Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register
about
Advances in rheumatology: new targeted therapeuticsWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapyWorking status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.Serious infections with antirheumatic therapy: are biologicals worse?A longitudinal evaluation of the Center for Epidemiologic Studies-Depression scale (CES-D) in a rheumatoid arthritis population using Rasch analysisOlder age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritisCo-morbidity in patients with early rheumatoid arthritis - inflammation mattersMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesTumor necrosis factor inhibitors and infection complications.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapyA Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.Hypertension in rheumatoid arthritis.Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study.The importance of rheumatology biologic registries in Latin America.Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis.Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study.A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome.Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.The British Society for Rheumatology Biologics Register: 6 years on
P2860
Q21093257-A0EB210C-2AC1-4A8D-AA4B-EC04623B8DE2Q28074148-90FB0390-DBB6-4E38-8A6F-52474B91537FQ31148620-5BAE5F7F-E7EB-41E8-ADF6-34BAC6438554Q33406652-F62FAC28-3DBF-4DB9-BFC2-9D60EF844F5DQ33529391-14A51AFA-DF86-4EF3-95D8-F2BA4F03F0BDQ33602465-6D1E5925-3835-4BE5-8782-FB9F1B12FA2AQ33836681-0710E79F-AB12-40C9-9AD3-F044E885EE0AQ33990812-40E478F7-B1EB-4228-BD04-5A51287658E3Q34654104-257A0D3C-279E-4773-8976-8FA7D6D46BE6Q35638259-4230CB13-55D6-49B8-B4E0-3499CDB0AF8CQ35945937-20AF31D0-4913-462A-A8E8-00909C6B2213Q36028729-6A62496B-08EE-42CA-B660-1CF98D332406Q36099620-3033C529-B2BF-4A3C-8219-3EB3A007F4D2Q36102004-0FF459BC-1492-485A-B751-A698ECCB48F7Q36220832-78BCF4F9-F030-4ABA-96E4-53FEE9F0652DQ36388001-23405030-0BD4-4164-87AB-FFCCA5FBE355Q36513993-9DFA70CF-F041-48DE-A03A-CE87E17D5979Q36724093-E3118D1D-8DBD-40D4-9A7B-D1F21B4A2525Q36806922-626A12FA-4060-486D-AFB1-864C7AE48368Q37000109-AAD9E543-5713-41CF-9E25-DFA07C676B1FQ37062611-3629C1D7-E2F9-4820-82F3-C4E1167F1CD2Q37100388-4337527A-C982-47A4-9DEA-1A986A9D3588Q37158219-BE6775CA-1685-4BF7-ABD9-A714B0E4EEE8Q37177593-2C96C41F-B64A-40F8-AA8E-788C9AC43190Q37658783-5D297DF7-D6AF-4524-96E3-D17ECC0F4E39Q38069473-1D7DAB60-C37D-41C1-88BD-0E20FC97E0B5Q38301639-75E6DDB4-43CF-433A-9B9D-C50705CBCF94Q43424128-1740609C-4716-4A89-B40A-F71D80630B08Q48069664-026E9464-C46D-4044-979E-14A3CD4253B0Q51131123-D4592BEF-5C46-4A71-B769-1E9AF591C60EQ53121954-A7FD9EE6-2799-4D92-A5FA-10F951438D8EQ55098455-05F733B1-F4B2-407E-AE2E-2CE3D499DB48Q57751289-0B42847E-38B3-4045-B9BC-824F841978BA
P2860
Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Baseline comorbidity levels in ...... om a national patient register
@ast
Baseline comorbidity levels in ...... om a national patient register
@en
type
label
Baseline comorbidity levels in ...... om a national patient register
@ast
Baseline comorbidity levels in ...... om a national patient register
@en
prefLabel
Baseline comorbidity levels in ...... om a national patient register
@ast
Baseline comorbidity levels in ...... om a national patient register
@en
P2093
P2860
P356
P1476
Baseline comorbidity levels in ...... om a national patient register
@en
P2093
BSRBR Control Centre Consortium
British Society for Rheumatology Biologics Register
P2860
P304
P356
10.1136/ARD.2005.043158
P407
P577
2005-12-08T00:00:00Z